Top 3 Undervalued Small Caps In The United Kingdom With Insider Action October 2024
In This Article:
The United Kingdom's market has been experiencing turbulence, with the FTSE 100 closing lower amid weak trade data from China and broader global economic concerns. Despite these challenges, small-cap stocks often present unique opportunities for investors, particularly those that show signs of being undervalued and have insider action indicating confidence in their potential.
Top 10 Undervalued Small Caps With Insider Buying In The United Kingdom
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Dr. Martens | 7.8x | 0.6x | 40.04% | ★★★★★★ |
| Domino's Pizza Group | 15.2x | 1.7x | 39.05% | ★★★★★☆ |
| C&C Group | NA | 0.5x | 44.71% | ★★★★★☆ |
| Bytes Technology Group | 26.5x | 6.0x | 5.49% | ★★★★☆☆ |
| CVS Group | 31.0x | 1.3x | 41.39% | ★★★★☆☆ |
| Essentra | 732.1x | 1.4x | 37.04% | ★★★★☆☆ |
| Genus | 166.4x | 2.0x | -0.52% | ★★★★☆☆ |
| NWF Group | 8.8x | 0.1x | 34.98% | ★★★☆☆☆ |
| Alpha Group International | 9.9x | 4.6x | -24.24% | ★★★☆☆☆ |
| Harworth Group | 12.5x | 6.5x | -620.87% | ★★★☆☆☆ |
Let's uncover some gems from our specialized screener.
Dr. Martens
Simply Wall St Value Rating: ★★★★★★
Overview: Dr. Martens is a renowned footwear company primarily engaged in the design, manufacturing, and sale of iconic boots and shoes, with a market capitalization of approximately ￡2.50 billion.
Operations: Dr. Martens generates revenue primarily from its footwear segment, with a gross profit margin of 65.58% as of September 30, 2024. The company's operating expenses include significant costs in general and administrative areas, which have reached ￡377.70 million for the same period.
PE: 7.8x
Dr. Martens, a notable player in the UK market, has seen insider confidence with share purchases in Q2 2024. Despite its high debt levels and reliance on external borrowing, earnings are forecast to grow at 5.88% annually. The company’s profit margins have dipped from 12.9% last year to 7.9%. Additionally, recent investor activism by Sparta Capital Management Ltd concluded without further discussions post-July AGM results announcement on July 11, 2024.
Genus
Simply Wall St Value Rating: ★★★★☆☆
Overview: Genus is a company specializing in animal genetics, with operations in bovine and porcine breeding, and a market cap of approximately ￡2.50 billion.
Operations: Genus generates revenue through its Genus ABS and Genus PIC segments, with the latter contributing ￡352.5 million. The company's gross profit margin has shown significant fluctuations, peaking at 68.02% in March 2024, while net income margins have varied widely, reaching up to 14.05% in December 2017 but dropping to lower levels in recent periods.